Keywords: tarceva, plus, avastin, miss, ph, iii, endpoint

Tarceva plus Avastin miss Ph III endpoint

Article | 13 October 2008

Print This

A combination of Tarceva (erlotinib) and Avastin (bevacizumab) in lung cancer patients who had not responded to chemotherapy failed to ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in